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a b s t r a C t
background: the aim of colorectal cancer screening is to 
improve prognosis by the detection of early cancer and 
precursor stages. We compared the stage distribution 
of asymptomatic colorectal cancer patients detected by a 
positive immunochemical or guaiac-based faecal occult 
blood test (fobt) with symptomatic colorectal cancer 
patients. 
methods: in a longitudinal cohort study tumour stages 
were assessed in 144 symptomatic (mean age 69.3 years, 
56% male) and 41 asymptomatic colorectal cancer patients 
(mean age 64.9 years, 56% male) of which 11 were detected 
with guaiac fobts (G-fobt, Hemoccult-ii®) and 30 with 
immunochemical fobts (i-fobt, oCsensor®). stage 
distributions were used to calculate average stage specific 
predicted five-year survival rates and to analyse group 
differences with Wilcoxon log-rank test.
results: Colorectal cancer was detected in significantly 
earlier stages in symptomatic compared with asymptomatic 
patients (p<0.0001). average stage specific predicted 
five-year survival was 59.1% in symptomatic and 76.6% in 
asymptomatic patients. Compared with the symptomatic 
patients the stage distribution for colorectal cancer patients 
detected with Hemoccult-ii was not significantly different 
(p=0.29), whereas colorectal cancer was detected at 
significantly earlier stages with the oCsensor (p<0.0001). 
treatment could be confined to colonoscopy in 27% of 
the asymptomatic patients compared with 3% of the 
symptomatic patients (p<0.0001). Cancer distribution 
over the colon was comparable between symptomatic and 
asymptomatic patients (p=0.3).
Conclusions: Compared with symptomatic patients, 
patients detected by fobt and especially immunochemical 
fobt, presented significantly more often at earlier stages 
suggesting increased survival. additionally treatment could 
more often be confined to colonoscopy.
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i n t r o d U C t i o n
Colorectal cancer is, after breast cancer, the second most 
frequent cancer in women, and after lung and prostate 
cancer, the third most frequent cancer in men in the 
Netherlands. The lifetime risk of developing colorectal 
cancer is approximately 6% (www.IKCnet.nl). In 2003, 
colorectal cancer was responsible for more than 56,000 
life-years lost and for 70,000 disability adjusted life-years 
in the Netherlands. Total costs for management of 
colorectal cancer patients amounted to 230 million euros.1 
The ageing population will have an enormous impact on 
the incidence of colorectal cancer and costs in the near 
future. Until 2025, the incidence of colorectal cancer will 
gradually increase by 40% in the Netherlands and medical 
costs for colorectal cancer patients will considerably 
increase due to growing application of biologicals.2 When 
colorectal cancer is detected as a result of symptoms, the 
prognosis is still rather poor with an average five-year 
survival between 50 to 60% (www.IKCnet.nl).3 In order 
to improve the prognosis of colorectal cancer, colorectal 
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cancer should be detected in earlier stages or even 
precursor stages. Colorectal cancer is a heterogeneous 
disease arising from a complex series of molecular events. 
The successive evolution of normal colonic mucosa 
to a benign adenoma, then to an adenomatous polyp 
containing cancer, and then to a potentially life-threatening 
invasive cancer is associated with a series of genetic events 
occurring over a period of approximately ten years.4 So, 
many years pass before colorectal cancer becomes clinically 
manifest and therefore there is an opportunity to improve 
prognosis by early detection of colorectal cancer with 
screening.
In 2006, colorectal cancer screening studies were started 
in the Netherlands randomly employing two different 
types of faecal occult blood tests (FOBTs): guaiac-based 
FOBTs and immunochemical FOBTs. In order to verify 
if prognosis of colorectal cancer is improved by FOBT 
screening and if improvement depends on the type of 
FOBT, we compared the stage distribution of colorectal 
cancer patients detected as a result of FOBT screening with 
colorectal cancer patients detected because of symptoms.
m a t e r i a l s  a n d  m e t H o d s
Between July 2006 and March 2007, asymptomatic 
subjects with a positive FOBT were invited for colonoscopy. 
These subjects were recruited from two colorectal 
cancer screening studies in the Netherlands with a 
comparable design, registered at Current Controlled 
Trials (ISRCTN57917442). All invited participants were 
asymptomatic, between 50 and 75 years of age and without 
apparent family history of colorectal cancer. Data from 
the largest of the two studies comparing the performance 
of two types of FOBTs, supported by the Netherlands 
Organisation for Health Research and Development 
(ZonMW: number 50-50115-98-060, project 63000004), 
were published previously.5 From the patients with 
colorectal cancer detected in these studies, the following 
data were collected: age, gender, location of the tumour, 
surgical or endoscopic treatment and TNM classification. 
These data were also collected from 144 consecutive 
symptomatic colorectal cancer patients without a family 
history of colorectal cancer in the same region in the 
Netherlands and in the same period, from July 2006 to 
March 2007. Tumour staging was performed according to 
the American Joint Committee on Cancer (AJCC) system, 
also called the TNM system, which describes stages 
using Roman numerals I through IV. Three experienced 
pathologists staged all the detected colorectal cancers of 
both the symptomatic and the asymptomatic patients. 
According to data from the Surveillance, Epidemiology, and 
End Results (SEER) programme, each stage has an average 
stage specific five-year survival (table 1).6 The follow-up 
after our study was too short to measure actual five-year 
survival and furthermore actual five-year survival would 
have to be corrected for over-diagnosis and lead-time bias, 
the extent of which is largely unknown. Therefore the 
stage specific average five-year survival rates were used to 
predict the five-year survival of the patients in our study 
group. For each colorectal cancer stage we assumed that 
the five-year survival would eventually prove to be identical 
for symptomatic or asymptomatic patients and identical 
to the SEER data. Of course this approximation method 
has certain drawbacks, but also advantages, which we will 
discuss in the discussion.
In the asymptomatic patients participating in the colorectal 
cancer screening study, the type of FOBT was also 
registered.5 Two types of FOBT were used, a guaiac-based 
FOBT (Hemoccult-II®) and an immunochemical 
based FOBT (OCSensor®). A specific advantage of the 
OCSensor® is that the test is quantitative allowing the 
cut-off value for positivity to be changed. As threshold 
for positivity, the manufacturer recommends a cut-off 
value of 100 ng/ml, applied in several studies.7-12 The 
literature as well as data provided by the manufacturer 
show that the test results of the OCSensor® are reliable in 
the range from 50 ng/ml to 2000 ng/ml.13 In the previous 
publication in Gastroenterology we compared the guaiac 
FOBT Hemoccult-II® with the I-FOBT OCSensor®. In 
that publication, for generalisability with the previous 
studies, we presented data for the I-FOBT with a cut-off 
value of 100 ng/ml. However, we invited all patients 
for colonoscopy with an I-FOBT result of ≥50 ng/ml, 
corresponding to about 10 µg haemoglobin per gram 
faeces.14 In the current study we use the data of all invited 
patients with a cut-off value of 50 ng/ml. 
With immunochemical faecal occult blood tests, as little 
as 0.3 ml of daily blood loss in the stool can be detected.15 
In contrast, the Hemoccult-II® test is a qualitative test 
in which the minimal amount of blood that can be 
table 1. Stage specific average five-year survival rates 
for colorectal cancer
t n m dukes stage 5-year 
survival*
Tis N0 M0 - 0 98%
T1 N0 M0 A I 93%
T2 N0 M0 A I 93%
T3 N0 M0 B1 IIA 85%
T4 N0 M0 B2 IIB 72%
T1,2 N1 M0 C1 IIIA 83%
T3,4 N1 M0 - IIIB 64%
Each T N2 M0 C2 IIIC 44%
Each T Each N M1 D IV 8%
*according to data from the surveillance, epidemiology, and end 
results (seer) programme.
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detected in faeces is probably about ten times higher than 
immunochemical FOBTs.15,16 Therefore, we speculated that 
the immunochemical FOBT OCSensor® detects colorectal 
cancer at earlier stages. 
We calculated descriptive statistics of the symptomatic and 
asymptomatic study populations. We used nonparametric 
analysis with the Wilcoxon log-rank test to compare the 
stage distribution between the two groups. Statistical 
significance was accepted if the level of probability of a 
type I error was ≤5% (p<0.05). Statistical analyses were 
performed with SAS system for windows, software version 
8.02 (SAS Institute Inc., Cary, NC, USA). 
r e s U l t s
Colonoscopies in the asymptomatic group with a positive 
FOBT revealed in total 41 patients with colorectal cancer 
(23 male, 18 female; mean age 64.9 years, range 53 to 75 
years). Nine of the tumours were located in the rectum, 
19 in the sigmoid, three in the descending colon, one 
in the splenic flexure, two in the transverse colon, one 
in the hepatic flexure, four in the ascending colon, and 
two in the caecum (table 2). Twenty of the tumours were 
classified as stage I, six as stage IIA, three as stage IIIA, 
five as stage IIIB, four as stage IIIC, and three as stage IV 
(table 3). The average predicted five-year survival deduced 
from the TNM staging system and SEER programme 
(table 1) in this group of 41 patients was 76.6 (SD 25%). In 
11 (27%) of these 41 patients tumour treatment could be 
confined to endoscopy. Tumours were found in 11 patients 
with a positive Hemoccult-II® and in 30 patients with a 
positive OCSensor®. The predicted five-year survival for 
the patients with a positive Hemoccult-II® test was 60.5 
(SD 37%), and for the patients with a positive OCSensor® 
82.4 (SD 16%). 
Colonoscopies performed in subjects referred with 
symptoms, such as visible blood loss and changed bowel 
habits, revealed 144 patients with colorectal cancer (81 
male, 63 female; mean age 69.3 years, range 32 to 93 
years). Sixty-one of the tumours were located in the 
rectum, 33 in the sigmoid, three in the descending colon, 
three in the splenic flexure, five in the transverse colon, 
five in the hepatic flexure, 17 in the ascending colon, 15 
in the caecum and for four tumours the specific location 
was uncertain (table 2). Two patients had a double 
tumour and these patients were staged according to 
the most advanced carcinoma. Six of the patients were 
classified as stage I, 23 as stage IIA, 43 as stage IIB, 15 
as stage IIIA, 12 as stage IIIB, 13 as stage IIIC, and 32 as 
stage IV (table 3). The predicted five-year survival for this 
group of 144 patients was 59.1 (SD 29%). In four (3%) of 
these 144 patients tumour removal could be confined to 
endoscopy. 
Colorectal cancer was detected significantly earlier in 
symptomatic patients compared with asymptomatic 
patients (p<0.0001). Average stage specific predicted 
five-year survival was 59.1% in symptomatic and 76.6% 
in asymptomatic patients. Additionally, treatment for 
colorectal cancer could be confined to colonoscopy in 
27% of the asymptomatic patients compared with 3% of 
the symptomatic patients (p<0.0001). Ten (24%) of the 
colorectal cancer tumours in asymptomatic patients and 
45 (31%) of the colorectal cancer tumours in symptomatic 
patients were located proximal of the descending colon 
(p=0.3). 
Compared with the symptomatic patients the stage 
distribution for colorectal cancer patients detected with 
Hemoccult-II was not significantly different (p=0.29), 
whereas colorectal cancer was detected significantly earlier 
in patients detected with OCSensor compared with the 
symptomatic patients (p<0.0001). The average predicted 
five-year survival was 82.4% for the asymptomatic patients 
detected with the OCSensor® and 60.5% for the patients 
detected with the Hemoccult-II®. 
table 2. Location of colorectal cancer in symptomatic 
and asymptomatic patients
Colorectal cancer 
location
symptomatic 
patients 
n=144* (%)
asymptomatic 
patients  
n=41 (%)
Rectum 61 (42%) 9 (22%)
Sigmoid colon 33 (23%) 19 (46%)
Descending colon 3 (2%) 3 (7%)
Splenic flexure 3 (2%) 1 (2%)
Transverse colon 5 (3%) 2 (5%)
Hepatic flexure 5 (3%) 1 (2%)
Ascending colon 17 (12%) 4 (10%)
Caecum 15 (10%) 2 (5%)
Unknown 4 ( 3%) - (0%)
*two patients had two concurrent colorectal tumours.
table 3. Staging of colorectal cancer in symptomatic 
and asymptomatic patients
Colorectal cancer  
stage
symptomatic 
patients 
n=144 (100%)
asymptomatic 
patients  
n=41 (100%)
I 6 (4%) 20 (49%)
IIA 23 (16%) 6 (15%)
IIB 43 (30%) 0 (0%)
IIIA 15 (10%) 3 (7%)
IIIB 12 (8%) 5 (12%)
IIIC 13 (9%) 4 (10%)
IV 32 (22%) 3 (7%)
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d i s C U s s i o n
In this study we demonstrated that colorectal cancer in 
asymptomatic persons aged between 50 and 75 years with 
a positive FOBT is on average detected at a significantly 
earlier stage compared with symptomatic subjects with 
colorectal cancer diagnosed in the same time period and 
in the same geographical region. In addition, treatment of 
colorectal cancer could significantly more often be confined 
to colonoscopy in the asymptomatic screening group than 
in the symptomatic group. The most important finding in 
this study was that, compared with symptomatic patients, 
colorectal cancer was detected in significantly earlier 
stages for the patients detected with the I-FOBT, but not 
for patients detected with the G-FOBT.
We have compared the data from our study with data from 
a German study by Hüppe et al. For easy comparison with 
our study we calculated the gain in predicted five-year 
colorectal cancer survival according to stage distribution 
from the data in their study in 5066 asymptomatic patients 
(participating in colonoscopy screening) and in 4099 
symptomatic patients.17 The 18% gain in survival from 
their data compares well with the 22% gain in average 
predicted survival we observed with FOBT screening. In 
addition Hüppe et al. had followed up their population for 
up to five years (on average 33 months). Up to the time of 
their publication no subjects in the screening group had 
died compared with 20% of the symptomatic colorectal 
cancer patients, confirming the predicted gain in five-year 
survival according to stage distribution.17 We propose 
this indicates that the stage distribution of colorectal 
cancer detected by primary colonoscopy screening is 
comparable with the stage distribution of colorectal cancer 
detected by faecal occult blood testing. Additionally the 
follow-up data by Hüppe et al. indicate that colorectal 
cancer survival predicted by stage distribution might 
on average correlate well with actual survival. We think 
this is interesting for policy makers who are considering 
implementing colorectal cancer screening with either 
primary colonoscopy or FOBT.
Another important finding of our study was the difference 
that we observed in the stage distribution between 
subjects with colorectal cancer detected after a positive 
Hemoccult-II® test, compared with a positive OCSensor® 
test. Both the Hemoccult-II® test and the OCSensor® 
test are developed to detect haemoglobin in faeces. In 
contrast to the Hemoccult-II® test, the OCSensor® 
test is specific for human haemoglobin and the test is 
quantitative, allowing the cut-off values for positivity to 
be shifted. The Hemoccult-II® test is probably at least ten 
times less sensitive to haemoglobin compared with the 
OCSensor® test.15,16 The stage distribution of colorectal 
cancer patients detected with the OCSensor® in this study 
was significantly better than the stage distribution in the 
symptomatic patients. In contrast, the stage distribution of 
colorectal cancer patients detected with the Hemoccult-II® 
was not significantly different from the symptomatic 
patients. Therefore we propose that colorectal cancer 
patients detected by a positive OCSensor® can probably 
on average expect to have an increased five-year survival 
compared with those with a positive Hemoccult-II®.
Although slightly more proximal colorectal cancers were 
detected in the symptomatic patients compared with the 
asymptomatic patients, this difference was not statistically 
significant. Therefore, tumours in the proximal colon 
are also detected by FOBT. For the OCSensor® this was 
confirmed in a recent study, where it was shown that the 
amount of blood in the stool detected in patients with 
proximal colorectal cancer is lower than in distal colorectal 
cancer, but never below the cut-off value of 50 ng/ml that 
we used in our study population.14 In another study with 
a different immunochemical FOBT (Magstream 1000®), 
a lower sensitivity for proximal compared with distal 
colorectal cancer was reported, but this difference was 
not statistically significant.18 Wexner et al. demonstrated 
there was no difference in colorectal cancer location 
for Hemoccult-II® negative and Hemoccult-II® positive 
colorectal cancer patients.19 Fujita et al. also failed to detect 
any differences in colorectal cancer distribution over the 
colon in asymptomatic patients screened with guaiac slides 
compared with symptomatic patients.20 
C o n C l U s i o n
We demonstrated that colorectal cancer is detected at 
significantly earlier stages in asymptomatic patients by a 
positive FOBT compared with symptomatic patients. In 
addition, treatment of colorectal cancer could be confined 
to colonoscopy in significantly more asymptomatic patients 
with a positive FOBT than in the symptomatic group. 
Furthermore, there was no difference in distribution of 
colorectal cancer over the colon between the asymptomatic 
and symptomatic colorectal cancer patients, indicating 
that tumours in the proximal colon are also detected by 
FOBT. Colorectal cancer was not detected at significantly 
earlier stages in patients detected with the Hemoccult-II 
compared with symptomatic patients. However, colorectal 
cancer was detected in significantly earlier stages in 
patients detected with the OCSensor compared with 
symptomatic patients. 
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